Skip to content

Brain Activity Associated With Inhibition of Action in Attention-deficit

Assessment of Brain Activity Associated With Inhibition of Action in Attention-deficit Hyperactivity Disorder

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04768556
Acronym
INHIB'MOV
Enrollment
45
Registered
2021-02-24
Start date
2021-03-17
Completion date
2023-07-27
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit, Hyperactivity Disorder

Keywords

KEYWORDS: Inhibitory control, time-frequency

Brief summary

Inhibitory control allows individuals to suppress unwanted actions and to resist irrelevant stimuli. It is thought to be a core deficit in Attention-deficit/hyperactivity disorder (ADHD). The present study aims at evaluating this deficit in adults with ADHD. Executive and inhibitory capacities, as well as the neural mechanisms underlying inhibitory control, will be assessed in adults with ADHD and two control groups of participants.

Detailed description

ADHD is a psychiatric disorder characterized by symptoms of inattention, hyperactivity, and impulsivity (DSM-V, 2013). An impairment of inhibitory control has been suggested as the primary deficit in children with ADHD, which is thought to cause secondary impairments in executive functioning. A few studies investigated executive capacities in adults with ADHD. Specifically, an impairment in action inhibition has been reported in ADHD participants. Moreover, inhibition of action is often associated with distinctive electroencephalographic (EEG) correlates. The present study aim at combining both novel inhibitory control measurement techniques and EEG analysis in temporal and frequency domains to assess the sensitivity and the specificity of an inhibitory deficit in adults with ADHD. This is part of an improvement in the procedures for diagnosing ADHD syndrome and its functional evaluation. The study will analyze the EEG activity associated with two stop-signal tasks requiring inhibitory capacities. A set of other cognitive skills will also be evaluated during a neuropsychological assessment. The results of ADHD patients will be compared with those of a control group (healthy volunteers) to assess the sensitivity of an inhibition deficit to the disorder. These same results will also be compared with those of a second control group (patients with a negative diagnosis of ADHD) to assess the specificity of the inhibitory deficit. This experimental strategy results in the involvement of three groups of participants (ADHD patients and two control groups) in three visits (neuropsychological assessment and two EEG sessions).

Interventions

OTHEREEG experimental sessions 1

An EEG experimentation session on the stop-signal task of inhibiting a prepared discrete graphic action.

OTHEREEG experimental sessions 2

An EEG experimentation session on the stop-signal task of inhibiting an ongoing rhythmic action

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER
Centre National de la Recherche Scientifique, France
CollaboratorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

This study is pathophysiological, monocentric, comparative, and controlled with 3 groups compared: ADHD patients, control patients (negative diagnosis of ADHD), and healthy volunteers. The three groups will complete the same protocol, in the same manner.

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Age between 18 and 50, * Visual, auditory (authorized apparatus), motor skills suitable for the proper realization of neuropsychological tests, * Being right-handed, * Free, informed and written consent signed by the participant and the investigator * Person affiliated or beneficiary of a social security scheme. * For the ADHD group: * Diagnosis of ADHD according to DSM-V criteria (APA, 2013), For the patient control group: • Patient who consulted for a cognitive complaint and for whom the diagnosis of ADHD was rejected according to the criteria of DSM-V (APA, 2013).

Exclusion criteria

* General or progressive neurological disease resulting in cognitive impairment (multiple sclerosis, Parkinson's disease, stroke, etc.), * Insufficient linguistic level in French to participate in neuropsychological assessment, * Patient placed under judicial protection or under another protective regime, * Severe depression according to DSM-V criteria (APA, 2013), * Autism spectrum disorder, developmental coordination disorder. -For the healthy voluntary control group: * Presence of a cognitive complaint or pathology which may impair his cognitive functions

Design outcomes

Primary

MeasureTime frameDescription
EEG correlates of inhibition2 weeksThe main objective of this study is to evaluate, by electrophysiological measures, the presence of a deficit of action inhibition in adults with ADHD. To this end, the EEG correlates of inhibition will be compared between participants in the three groups. Thus, the ERP (N2 / P3) and ERSP (Theta, Delta) variations observed in terms of amplitude and latency in the stop-signal task tests will be computed in each of the three groups.

Secondary

MeasureTime frameDescription
Inhibition performance from a discrete-action task2 weeksThe inhibition performance from a discrete-action task, expressed as an SSRT (in ms). According to the horse-race model of inhibition, this latency is estimated based on the response time and the response probability obtained by the participants when responding to the GO and STOP stimuli used in the task (following recent guidelines from Verbruggen et al., 2019).
Inhibition performance from a rhythmic-action task2 weeksThe inhibition performance from a rhythmic-action task, expressed as stop-signal reaction time (SSRT, in ms). This latency is measured by identifying a statistical deviation evoked by the STOP signal in the participants' movement on a graphic tablet (following the procedure described in Hervault et al., 2019).

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJeremie PARIENTE, MD PhD

University Hospital, Toulouse

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026